AstraAstraZeneca.JPG” style=”padding: 10px” width=”289″ />

British-Swedish drugmaker AstraZeneca has received marketing approval from the European Commission (EC) for Duaklir Genuair (aclidinium bromide/formoterol fumarate 340/12mcg).

The company obtained marketing authorisation for the drug to be used as a maintenance bronchodilator treatment, to relieve symptoms in adult patients with chronic obstructive pulmonary disease (COPD).

Duaklir is a fixed-dose combination of long-acting muscarinic-antagonist (LAMA), Eklira (aclidinium bromide), and long-acting beta-agonist (LABA), formoterol.

AstraZeneca global medicines development executive vice-president Briggs Morrison said: "We are pleased to receive European regulatory approval for Duaklir Genuair as an innovative treatment for patients with COPD.

"AstraZeneca obtained marketing authorisation for the drug to be used as a maintenance bronchodilator treatment, to relieve symptoms in adult patients with chronic obstructive pulmonary disease (COPD)."

"Patients need treatments that can help to improve their lung function and allow them to better manage the daily and debilitating symptoms of their condition, in turn improving their overall quality of life."

Approval was based on efficacy and safety data from more than 2,000 patients in 11 clinical trials, conducted in 29 countries worldwide.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Following the strategic business combination of Almirall‘s respiratory portfolio, AstraZeneca owns the rights to develop and commercialise Duaklir in the European Union (EU).

The approval allows the company to market Duaklir in both dry powder and pressurised metered dose devices.

AstraZeneca noted that the twice-daily therapy is the only LAMA/LABA combination to show statistically significant improvement in breathlessness compared to individual therapies. It is administered by the Genuair dry powder inhaler device.


Image: AstraZeneca’s R&D site in Mölndal, Sweden. Photo: courtesy of Erik031.